Highly Efficient Elimination of Colorectal Tumor-Initiating Cells by an EpCAM/CD3-Bispecific Antibody Engaging Human T Cells
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
With their resistance to genotoxic and anti-proliferative drugs and potential to grow tumors and metastases from very few cells, cancer stem or tumor-initiating cells (TICs) are a severe limitation for the treatment of cancer by conventional therapies. Here, we explored whether human T cells that are redirected via an EpCAM/CD3-bispecific antibody called MT110 can lyse colorectal TICs and prevent tumor growth from TICs. MT110 recognizes EpCAM, a cell adhesion molecule expressed on TICs from diverse human carcinoma, which was recently shown to promote tumor growth through engagement of elements of the wnt pathway. MT110 was highly potent in mediating complete redirected lysis of KRAS-, PI3 kinase- and BRAF-mutated colorectal TICs, as demonstrated in a soft agar assay. In immunodeficient mice, MT110 prevented growth of tumors from a 5,000-fold excess of a minimally tumorigenic TIC dose. T cells engaged by MT110 may provide a potent therapeutic means to eradicate TICs and bulk tumor cells derived thereof.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“For example, EpCAM/CD3 BiTEs eliminated CSCs in colon cancer cell lines and primary CSCs isolated from colon cancer patient samples and blocked CRC xenograft tumor growth [186,187].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [186]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prospective identification of tumorigenic breast cancer cells
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0530291100 · Cited by 10,370
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516 · cited 1×
“Moreover, in colorectal cancer the presence of T cells in tumors correlates with survival of patients [50].”
BackgroundIdentification and expansion of human colon-cancer-initiating cells
Ricci-Vitiani, L., Lombardi, D. G., Pilozzi, E., Biffoni, M., Todaro, M., Peschle, C., & De Maria, R. (2007) · Nature · doi:10.1038/nature05384 · Cited by 3,998 · cited 1×
“Moreover, independent reports showed expression of EpCAM on colorectal TICs [5,9,47,48], with evidence for a functional role of EpCAM in tumorigenesis [5,20].”
BackgroundCancer stem cells in solid tumours: accumulating evidence and unresolved questions
Visvader, J. E., & Lindeman, G. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2499 · Cited by 3,429 · cited 1×
“In order to verify their cancer stem cell phenotype, TICs were analyzed by FACS staining for expression of established surface markers [18], and by using RT-PCR for expression of mRNAs coding for surface and intracellular marker proteins.”
MethodIdentification of Pancreatic Cancer Stem Cells
Li, C., Heidt, D. G., Dalerba, P., Burant, C. F., Zhang, L., Adsay, V., Wicha, M., Clarke, M. F., & Simeone, D. M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2030 · Cited by 3,339
Ben-Porath, I., Thomson, M. W., Carey, V. J., Ge, R., Bell, G. W., Regev, A., & Weinberg, R. A. (2008) · Nature Genetics · doi:10.1038/ng.127 · Cited by 2,523 · cited 1×
“Certain normal epithelial tissues and embryonic stem cells express EpCAM [24–26], but there is evidence to suggest that EpCAM on normal epithelial tissues is largely sequestered while it is accessible on the surface of cancer cells [27,28].”
BackgroundPhenotypic characterization of human colorectal cancer stem cells
Dalerba, P., Dylla, S. J., Park, I.-K., Liu, R., Wang, X., Cho, R. W., Hoey, T., Gurney, A., Huang, E. H., Simeone, D. M., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703478104 · Cited by 2,184 · cited 2×
“, from colorectal and pancreatic tumors, by using antibodies specific for epithelial cell adhesion molecule (EpCAM; also called ESA) [5,6].”
BackgroundTumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody
Bargou, R., Leo, E., Zugmaier, G., Klinger, M., Goebeler, M., Knop, S., Noppeney, R., Viardot, A., Hess, G., Schuler, M., et al. (2008) · Science · doi:10.1126/science.1158545 · Cited by 1,078 · cited 2×
“A CD19/CD3-bispecific BiTE antibody called blinatumomab showed high anti-tumor activity in relapsed non-Hodgkin’s lymphoma patients [40], providing clinical proof of concept for the therapeutic principle of BiTE antibodies.”
BackgroundSelf-citationPatrawala, L., Calhoun, T., Schneider-Broussard, R., Li, H., Bhatia, B., Tang, S., Reilly, J. G., Chandra, D., Zhou, J., Claypool, K., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209327 · Cited by 968 · cited 1×
“Furthermore, the expression of EpCAM and CD44 was shown to track with the tumorigenic phenotype of such cells [5,7– 10].”
BackgroundShmelkov, S. V., Butler, J. M., Hooper, A. T., Hormigo, A., Kushner, J., Milde, T., St. Clair, R., Baljevic, M., White, I., Jin, D. K., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34401 · Cited by 896
Module Map of Stem Cell Genes Guides Creation of Epithelial Cancer Stem Cells
Wong, D. J., Liu, H., Ridky, T. W., Cassarino, D., Segal, E., & Chang, H. Y. (2008) · Cell Stem Cell · doi:10.1016/j.stem.2008.02.009 · Cited by 720 · cited 1×
“The significance of TICs for cancer therapy and biology is therefore under intense research [1– 4].”
BackgroundNuclear signalling by tumour-associated antigen EpCAM
Maetzel, D., Denzel, S., Mack, B., Canis, M., Went, P., Benk, M., Kieu, C., Papior, P., Baeuerle, P. A., Munz, M., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1824 · Cited by 719 · cited 2×
“Involvement of EpCAM in wnt signaling [22] may ensure that a majority of TICs need to express EpCAM for proliferation and survival and that target loss may select a population of tumor cells with reduced tumorigenic potential.”
BackgroundSelf-citationEpCAM and α-Fetoprotein Expression Defines Novel Prognostic Subtypes of Hepatocellular Carcinoma
Yamashita, T., Forgues, M., Wang, W., Kim, J. W., Ye, Q., Jia, H., Budhu, A., Zanetti, K. A., Chen, Y., Qin, L.-X., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6013 · Cited by 717 · cited 1×
“In several human malignancies, including breast, ovarian, ampullary pancreas, gall bladder and liver cancers, EpCAM overexpression correlates with a poor survival prognosis of patients [13–17].”
BackgroundColorectal Cancer Stem Cells Are Enriched in Xenogeneic Tumors Following Chemotherapy
Dylla, S. J., Beviglia, L., Park, I.-K., Chartier, C., Raval, J., Ngan, L., Pickell, K., Aguilar, J., Lazetic, S., Smith-Berdan, S., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002428 · Cited by 589 · cited 1×
“Moreover, independent reports showed expression of EpCAM on colorectal TICs [5,9,47,48], with evidence for a functional role of EpCAM in tumorigenesis [5,20].”
BackgroundEpCAM (CD326) finding its role in cancer
Baeuerle, P. A., & Gires, O. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603494 · Cited by 527
Self-citationThe Emerging Role of EpCAM in Cancer and Stem Cell Signaling
Munz, M., Baeuerle, P. A., & Gires, O. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0654 · Cited by 515
Self-citationJhawer, M., Goel, S., Wilson, A. J., Montagna, C., Ling, Y.-H., Byun, D.-S., Nasser, S., Arango, D., Shin, J., Klampfer, L., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5659 · Cited by 460 · cited 1×
“Cells of the colorectal cancer line HT-29 have a mutated BRAF gene (V600E) and are relatively resistant to cytotoxicity by anti-EGFR antibody cetuximab [43].”
BackgroundLoupakis, F., Pollina, L., Stasi, I., Ruzzo, A., Scartozzi, M., Santini, D., Masi, G., Graziano, F., Cremolini, C., Rulli, E., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.2796 · Cited by 403 · cited 1×
“with signal inhibitory anti-EGFR therapeutics [45,46].”
Went, P., Vasei, M., Bubendorf, L., Terracciano, L., Tornillo, L., Riede, U., Kononen, J., Simon, R., Sauter, G., & Baeuerle, P. A. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602924 · Cited by 387 · cited 2×
“EpCAM is frequently expressed at high levels on primary tumors and metastases of most human adenocarcinoma [11,12].”
BackgroundSelf-citationThe carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation
Münz, M., Kieu, C., Mack, B., Schmitt, B., Zeidler, R., & Gires, O. (2004) · Oncogene · doi:10.1038/sj.onc.1207610 · Cited by 368
Self-citationOffner, S., Hofmeister, R., Romaniuk, A., Kufer, P., & Baeuerle, P. A. (2006) · Molecular Immunology · doi:10.1016/j.molimm.2005.03.007 · Cited by 365 · cited 1×
“We have shown in clinical [40] and preclinical studies [51] that effector memory T cells make the largest contribution to BiTE activity, and that redirected T cells can lyse tumor cells independent of T cell receptor specificity, MHC class I expression and the need for costimulation [30,34,35].”
BackgroundSelf-citationHoffmann, P., Hofmeister, R., Brischwein, K., Brandl, C., Crommer, S., Bargou, R., Itin, C., Prang, N., & Baeuerle, P. A. (2005) · International Journal of Cancer · doi:10.1002/ijc.20908 · Cited by 344
Self-citationEp-CAM overexpression in breast cancer as a predictor of survival
Gastl, G., Spizzo, G., Obrist, P., Dünser, M., & Mikuz, G. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03312-2 · Cited by 262 · cited 1×
“In several human malignancies, including breast, ovarian, ampullary pancreas, gall bladder and liver cancers, EpCAM overexpression correlates with a poor survival prognosis of patients [13–17].”
BackgroundBiTEs: bispecific antibody constructs with unique anti-tumor activity
Wolf, E., Hofmeister, R., Kufer, P., Schlereth, B., & Baeuerle, P. A. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03554-3 · Cited by 260 · cited 1×
“By their search and destroy mode of action and their high cytotoxic potential [30,31], T cells may be able to find widely disseminated, temporarily non-proliferating TICs.”
BackgroundSelf-citationBrischwein, K., Schlereth, B., Guller, B., Steiger, C., Wolf, A., Lutterbuese, R., Offner, S., Locher, M., Urbig, T., Raum, T., et al. (2006) · Molecular Immunology · doi:10.1016/j.molimm.2005.07.034 · Cited by 256 · cited 11×
“One (18 pM) or 100 ng/ml MT110 were sufficient to completely eliminate tumorigenic HT-29 cells while 0.01 ng/ml MT110, PBMC alone, or control BiTE antibodies solely binding CD3 or EpCAM had no effect on the number of colonies formed (Fig.”
BackgroundInfluentialSelf-citationHeinemann, V., Stintzing, S., Kirchner, T., Boeck, S., & Jung, A. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.11.005 · Cited by 203 · cited 1×
“with signal inhibitory anti-EGFR therapeutics [45,46].”
Spizzo, G., Went, P., Dirnhofer, S., Obrist, P., Moch, H., Baeuerle, P. A., Mueller-Holzner, E., Marth, C., Gastl, G., & Zeimet, A. G. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.03.035 · Cited by 201 · cited 1×
“In several human malignancies, including breast, ovarian, ampullary pancreas, gall bladder and liver cancers, EpCAM overexpression correlates with a poor survival prognosis of patients [13–17].”
BackgroundSelf-citationBiTE: Teaching antibodies to engage T-cells for cancer therapy.
Baeuerle, P. A., Kufer, P., & Bargou, R. C. (2009) · PubMed · Cited by 192
Self-citationCD44 and EpCAM: Cancer-Initiating Cell Markers
Marhaba, R., Klingbeil, P., Nuebel, T., Nazarenko, I., Buechler, M., & Zoeller, M. (2008) · Current Molecular Medicine · doi:10.2174/156652408786733667 · Cited by 192
Mode of cytotoxic action of T cell-engaging BiTE antibody MT110
Haas, C., Krinner, E., Brischwein, K., Hoffmann, P., Lutterbüse, R., Schlereth, B., Kufer, P., & Baeuerle, P. A. (2009) · Immunobiology · doi:10.1016/j.imbio.2008.11.014 · Cited by 178 · cited 1×
“We have shown in clinical [40] and preclinical studies [51] that effector memory T cells make the largest contribution to BiTE activity, and that redirected T cells can lyse tumor cells independent of T cell receptor specificity, MHC class I expression and the need for costimulation [30,34,35].”
BackgroundSelf-citationCancer Stem Cells: Controversial or Just Misunderstood?
Jordan, C. T. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.02.003 · Cited by 162 · cited 1×
“While mortalities of heart disease, stroke and infectious diseases (flu and pneumonia) have declined over the past 55 years by 64, 74 and 58%, overall cancer mortality did only decline by 5% (National Center for Health Statistics). One reason may be the resistance of so called cancer stem or tumor-initiating cells (TI…”
BackgroundA revival of bispecific antibodies
Kufer, P., Lutterbüse, R., & Baeuerle, P. A. (2004) · Trends in Biotechnology · doi:10.1016/j.tibtech.2004.03.006 · Cited by 157 · cited 1×
“The principle of BiTE antibodies has been reviewed in detail [30–33].”
BackgroundSelf-citationOn the abundance of EpCAM on cancer stem cells
Gires, O., Klein, C. A., & Baeuerle, P. A. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2499-c1 · Cited by 145
Self-citationSchlereth, B., Fichtner, I., Lorenczewski, G., Kleindienst, P., Brischwein, K., da Silva, A., Kufer, P., Lutterbuese, R., Junghahn, I., Kasimir-Bauer, S., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2637 · Cited by 132
Self-citationEpCAM expression in normal, non-pathological tissues
Schmelzer, E. (2007) · Frontiers in bioscience · doi:10.2741/2911 · Cited by 117 · cited 1×
“Certain normal epithelial tissues and embryonic stem cells express EpCAM [24–26], but there is evidence to suggest that EpCAM on normal epithelial tissues is largely sequestered while it is accessible on the surface of cancer cells [27,28].”
BackgroundEpCAM Is Involved in Maintenance of the Murine Embryonic Stem Cell Phenotype
González, B., Denzel, S., Mack, B., Conrad, M., & Gires, O. (2009) · Stem Cells · doi:10.1002/stem.97 · Cited by 113
Ep-CAM expression in pancreatic and ampullary carcinomas: frequency and prognostic relevance
Fong, D., Steurer, M., Obrist, P., Barbieri, V, Margreiter, R., Amberger, A., Laimer, K., Gastl, G., Tzankov, A., & Spizzo, G. (2008) · Journal of Clinical Pathology · doi:10.1136/jcp.2006.037333 · Cited by 112 · cited 1×
“In several human malignancies, including breast, ovarian, ampullary pancreas, gall bladder and liver cancers, EpCAM overexpression correlates with a poor survival prognosis of patients [13–17].”
BackgroundChen, H., Chu, R. Y.-Y., Hsu, P., Hsu, P.-I., Lu, J.-Y., Lai, K.-H., Tseng, H., Chou, N., Huang, M.-S., Tseng, C., et al. (2003) · Cancer Letters · doi:10.1016/j.canlet.2003.07.007 · Cited by 110 · cited 3×
“Under cell culture conditions in the presence of 10% fetal calf serum (FCS), TICs started to differentiate as shown by expression of E-cadherin [44] and a morphological change to a more epithelial phenotype (Figure S4B, Materials and Methods S1).”
InfluentialChaudry, M. A., Sales, K. M., Ruf, P., Lindhofer, H., & Winslet, M. C. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603505 · Cited by 97 · cited 1×
“EpCAM has been selected as target for many antibody- and vaccine-based therapeutic approaches of which several are in clinical development [11,23].”
BackgroundAmann, M., Brischwein, K., Lutterbuese, P., Parr, L., Petersen, L., Lorenczewski, G., Krinner, E., Bruckmeier, S., Lippold, S., Kischel, R., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2182 · Cited by 90 · cited 1×
“Indicative of a therapeutic window, studies in mice using a BiTE binding to murine EpCAM and murine CD3 demonstrated anti-tumor activity in the absence of damage to EpCAM-expressing normal epithelia [37,41,42] .”
BackgroundSelf-citationEvaluating Therapeutic Efficacy against Cancer Stem Cells: New Challenges Posed by a New Paradigm
Wang, J. C. Y. (2007) · Cell stem cell · doi:10.1016/j.stem.2007.10.005 · Cited by 70
McLaughlin, P. M. J., Harmsen, M. C., Dokter, W. H. A., Kroesen, B., van der Molen, H., Brinker, M. G. L., Hollema, H., Ruiters, M. H. J., Buys, C. H. C. M., & de Leij, L. F. M. H. (2001) · PubMed · Cited by 67
Amann, M., dÁrgouges, S., Lorenczewski, G., Brischwein, K., Kischel, R., Lutterbuese, R., Mangold, S., Rau, D., Volkland, J., Pflanz, S., et al. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181a1c097 · Cited by 63 · cited 1×
“Indicative of a therapeutic window, studies in mice using a BiTE binding to murine EpCAM and murine CD3 demonstrated anti-tumor activity in the absence of damage to EpCAM-expressing normal epithelia [37,41,42] .”
BackgroundSelf-citationSchlereth, B., Kleindienst, P., Fichtner, I., Lorenczewski, G., Brischwein, K., Lippold, S., da Silva, A., Locher, M., Kischel, R., Lutterbüse, R., et al. (2005) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-005-0082-x · Cited by 61 · cited 1×
“MT110 and related EpCAM-specific BiTE antibodies showed high anti-tumor activity in diverse animal models [29,37–39].”
BackgroundSelf-citationBispecific antibodies for polyclonal T-cell engagement.
Baeuerle, P. A., Kufer, P., & Lutterbüse, R. (2003) · PubMed · Cited by 50
Self-citationAmann, M., Friedrich, M., Lutterbuese, P., Vieser, E., Lorenczewski, G., Petersen, L., Brischwein, K., Kufer, P., Kischel, R., Baeuerle, P. A., et al. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0529-y · Cited by 41 · cited 1×
“Indicative of a therapeutic window, studies in mice using a BiTE binding to murine EpCAM and murine CD3 demonstrated anti-tumor activity in the absence of damage to EpCAM-expressing normal epithelia [37,41,42] .”
BackgroundSelf-citationCancer: Inappropriate Expression of Stem Cell Programs?
Wang, J. Y., & Armstrong, S. A. (2008) · Cell stem cell · doi:10.1016/j.stem.2008.03.014 · Cited by 29
Prince, S., Zeidman, A., Dekel, Y., Ram, E., & Koren, R. (2008) · American Journal of Clinical Pathology · doi:10.1309/h8jeeaeb69j3kynd · Cited by 27 · cited 1×
“In several human malignancies, including breast, ovarian, ampullary pancreas, gall bladder and liver cancers, EpCAM overexpression correlates with a poor survival prognosis of patients [13–17].”
BackgroundFriedrich, M., Drache, D., Amann, M., Filusch, S., Voelkel, M., Thomas, O. S., Baeuerle, P. A., & Rattel, B. (2010) · Cancer Research · doi:10.1158/1538-7445.am10-2433 · Cited by 2
Self-citationRationale for Treatment of Colorectal Cancer with EpCAM Targeting Therapeutics
Baeuerle, P. A., & Riethmüeller, G. (2009) · Wiley eBooks · doi:10.1002/9783527625970.ch10 · Cited by 1
Self-citation
Research works printed but not linked: 1
- R Kischel, 2009, Effector memory T cells make a major contribution to redirected target cell lysis by T cell-engaging BiTE antibody MT110., AACR 2009 poster presentation
Cited by
Bispecific T‐cell engagers for cancer immunotherapy
Huehls, A. M., Coupet, T. A., & Sentman, C. L. (2015) · Immunology & Cell Biology · doi:10.1038/icb.2014.93 · Cited by 466
EpCAM and its potential role in tumor-initiating cells
Imrich, S., Hachmeister, M., & Gires, O. (2012) · Cell Adhesion & Migration · doi:10.4161/cam.18953 · Cited by 202
“Thus, combinations of several markers are more reliable to characterize cells as TICs.”
BackgroundInfluentialMolecular Biology of Liver Cancer Stem Cells
Oishi, N., Yamashita, T., & Kaneko, S. (2014) · Liver Cancer · doi:10.1159/000343863 · Cited by 169
Targeting T cells to tumor cells using bispecific antibodies
Frankel, S. R., & Baeuerle, P. A. (2013) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2013.03.029 · Cited by 166
Self-citationT cell engaging bispecific antibody (T-BsAb): From technology to therapeutics
Wu, Z., & Cheung, N. V. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.08.005 · Cited by 150
Metadata
- Authors
- Herrmann, I., Baeuerle, P. A., Friedrich, M., Murr, A., Filusch, S., Rüttinger, D., Majdoub, M. W., Sharma, S., Kufer, P., Raum, T., & Münz, M.
- Affiliations
- University of California, Los Angeles (US)
- Corresponding author
- Baeuerle, Patrick A.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2010-10-18
- Volume
- 5
- Issue
- 10
- Pages
- e13474
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC2956687
- OpenAlex
- W2024837280
- Cited by
- 85
- References
- 50
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 4 · 2023: 5 · 2022: 2 · 2021: 3 · 2020: 9 · 2019: 7 · 2018: 3 · 2017: 7 · 2016: 2 · 2015: 7 · 2014: 8 · 2013: 10 · 2012: 13
- FWCI
- 3.95
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- cancer stem cells, EpCAM, CD3, bispecific antibodies, T cell redirection, adoptive T cell therapy, tumor cell lysis, KRAS mutation, BRAF mutation, Wnt signaling
- MeSH terms
- Epithelial Cell Adhesion Molecule, Animals, Antigens, Neoplasm, Flow Cytometry, Humans, T-Lymphocytes, Colorectal Neoplasms, Cell Adhesion Molecules, Mice, SCID, Mice, Inbred NOD, CD3 Complex, Antibodies, Bispecific, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.